ERAL1: A Potential Drug Target and Biomarker (G26284)

Target Name: ERAL1

NCBI ID: G26284

ERAL1

ERAL1: A Potential Drug Target and Biomarker

ERAL1 (Endoplasmic Reticulum-Associated Protein 1) is a protein that is expressed in most tissues of the body. It is a member of the endoplasmic reticulum-associated protein (ERP) family, which includes proteins that play important roles in the delivery and processing of proteins from the endoplasmic reticulum to various cell types.

One of the unique features of ERAL1 is its ability to interact with small molecules, including drugs that are used for therapeutic purposes. This has led to the hypothesis that ERAL1 may be a drug target or biomarker, and a number of studies have aimed at identifying potential drug targets or biomarkers associated with ERAL1.

ERAL1 has been shown to interact with a wide range of small molecules, including drugs that are used to treat a variety of diseases, such as cancer, neurodegenerative diseases, and psychiatric disorders. These interactions may be important for understanding the mechanisms of action of these drugs and for identifying new potential drug targets or biomarkers.

One of the most promising drug targets associated with ERAL1 is the protein p120GTP, which is a component of the endoplasmic reticulum transport system. p120GTP is known to interact with ERAL1 and has been shown to play a role in the delivery of proteins to the endoplasmic reticulum.

Studies have suggested that inhibiting the activity of p120GTP or modifying its structure may be a useful way to treat diseases that are characterized by the overproduction or underproduction of certain proteins, such as those involved in cancer, neurodegenerative diseases, or psychiatric disorders.

Another potential drug target associated with ERAL1 is the protein transmembrane protease serine 2 (TMPRSS2), which is involved in the production of several different proteins that are involved in cell signaling pathways. TMPRSS2 has been shown to interact with ERAL1 and may be a useful target for drugs that are used to treat diseases that are characterized by the overproduction or underproduction of certain proteins.

In addition to its potential as a drug target, ERAL1 has also been shown to be a potential biomarker for a number of diseases. For example, studies have suggested that changes in the level of ERAL1 may be an indicator of certain diseases, such as neurodegenerative diseases or cancer.

The ability of ERAL1 to interact with small molecules and to serve as a drug target or biomarker makes it an important area of research for scientists working in the field of pharmacology. Further studies are needed to fully understand the role of ERAL1 in disease and to identify new potential drug targets or biomarkers associated with this protein.

Protein Name: Era Like 12S Mitochondrial RRNA Chaperone 1

Functions: Probable GTPase that plays a role in the mitochondrial ribosomal small subunit assembly. Specifically binds the 12S mitochondrial rRNA (12S mt-rRNA) to a 33 nucleotide section delineating the 3' terminal stem-loop region. May act as a chaperone that protects the 12S mt-rRNA on the 28S mitoribosomal subunit during ribosomal small subunit assembly

The "ERAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets